文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Screening and Treatment Program to Eliminate Hepatitis C in Egypt.

作者信息

Waked Imam, Esmat Gamal, Elsharkawy Aisha, El-Serafy Magdy, Abdel-Razek Wael, Ghalab Reham, Elshishiney Galal, Salah Aysam, Abdel Megid Soad, Kabil Khaled, El-Sayed Manal H, Dabbous Hany, El Shazly Yehia, Abo Sliman Mohamed, Abou Hashem Khalid, Abdel Gawad Sayed, El Nahas Nevine, El Sobky Ahmed, El Sonbaty Sahar, El Tabakh Hamdy, Emad Ehab, Gemeah Hany, Hashem Amal, Hassany Mohamed, Hefnawy Naseif, Hemida Abdel N, Khadary Ayman, Labib Kamal, Mahmoud Faisal, Mamoun Said, Marei Tamer, Mekky Saad, Meshref Alsayeda, Othman Alaa, Ragab Omnia, Ramadan Elhag, Rehan Ahmed, Saad Tarek, Saeed Ramy, Sharshar Mohamed, Shawky Hesham, Shawky Mohamed, Shehata Wael, Soror Hanaa, Taha Mohsen, Talha Mahmoud, Tealaab Adel, Zein Mohamed, Hashish Alaa, Cordie Ahmed, Omar Yasser, Kamal Ehab, Ammar Islam, AbdAlla Mohamed, El Akel Wafaa, Doss Wahid, Zaid Hala

机构信息

From the Hepatology Department, National Liver Institute, Menoufia University, Shebeen El Kom (I.W., W.A.-R.), and the Endemic Medicine Department, Faculty of Medicine, Cairo University (G. Esmat, A.E., M.E.-S., A.C., W.E.A., W.D.), the Ministry of Health and Population (R.G., G. Elshishiney, A.S., S.A.M., M.A.S., K.A.H., S.A.G., N.E.N., A.E.S., S.E.S., H.E.T., E.E., H.G., A. Hashem, N.H., A.N.H., A.K., K.L., F.M., S. Mamoun, T.M., S. Mekky, A.M., A.O., O.R., E.R., A.R., T.S., R.S., M. Sharshar, H. Shawky, M. Shawky, W.S., H. Soror, M. Taha, M. Talha, A.T., M.Z., H.Z.), the National Committee for Control of Viral Hepatitis (K.K.), the Pediatrics Department (M.H.E.-S.), the Hepatology and Tropical Medicine Department (H.D.), and the Department of Medicine (Y.E.S., Y.O.), Ain Shams University, the Hepatology Department, National Hepatology and Tropical Medicine Research Institute (M.H.), the Communicable Diseases Control Cluster, World Health Organization (A. Hashish), the Medical Research Division, National Research Center (E.K., M.A.), and the Tropical Medicine Department, Al-Azhar University (I.A.), Cairo - all in Egypt.

出版信息

N Engl J Med. 2020 Mar 19;382(12):1166-1174. doi: 10.1056/NEJMsr1912628.


DOI:10.1056/NEJMsr1912628
PMID:32187475
Abstract
摘要

相似文献

[1]
Screening and Treatment Program to Eliminate Hepatitis C in Egypt.

N Engl J Med. 2020-3-19

[2]
Association between interleukin 28B polymorphism and sustained virological response to sofosbuvir plus daclatasvir in chronic hepatitis C genotype 4 Egyptian patients.

J Clin Pharm Ther. 2021-8

[3]
Sofosbuvir Causing Diabetes Mellitus: Is there a Link?

J Coll Physicians Surg Pak. 2018-5

[4]
Sofosbuvir-/Daclatasvir-based therapy for chronic HCV and HCV/hepatitis B virus coinfected patients in Egypt.

Trans R Soc Trop Med Hyg. 2020-2-7

[5]
Leading Role of Sofosbuvir/Daclatasvir in Achieving Hepatitis C Elimination in Egypt.

J Viral Hepat. 2025-7

[6]
MSF pushes down price of generic hepatitis C drugs to new low level.

BMJ. 2017-11-1

[7]
Evaluation of Glycated Haemoglobin (HbA1c) Level in Type 2 Diabetic Chronic HCV Non-cirrhotic Treatment-Naïve Egyptian Patients Eradicated with Sofosbuvir Plus Daclatasvir.

Curr Diabetes Rev. 2020

[8]
[Not Available].

MMW Fortschr Med. 2015-6

[9]
Direct-acting antiviral treatment failure in genotype 2 hepatitis C chronic infection.

J Viral Hepat. 2021-2

[10]
Response Tailored Protocol Versus the Fixed 12Weeks Course of Dual Sofosbuvir/Daclatasvir Treatment in Egyptian Patients With Chronic Hepatitis C Genotype-4 Infection: A Randomized, Open-label, Non-inferiority Trial.

EBioMedicine. 2017-5-17

引用本文的文献

[1]
Hepatitis C Virus: Epidemiological Challenges and Global Strategies for Elimination.

Viruses. 2025-7-31

[2]
Real-World Treatment Efficacy and Safety Profile of Sofosbuvir- and Velpatasvir-Based HCV Treatment in South Korea: Multicenter Prospective Study.

Viruses. 2025-7-4

[3]
Sensitive RP-HPLC method with fluorimetric detection for concurrent quantification of emtricitabine, Daclatasvir and Ledipasvir in human urine.

Sci Rep. 2025-7-1

[4]
Tyrosine kinase inhibitors were well-tolerated among patients with different etiologies of advanced HCC with lower survival in non-viral patients.

Sci Rep. 2025-6-27

[5]
Microelimination of Hepatitis C in Thailand, Phetchabun Model: Progress, Challenges, and Future Directions.

J Clin Med. 2025-6-3

[6]
A 2024 global report on national policies, programmes, and progress towards hepatitis C elimination: findings from 33 hepatitis elimination profiles.

Lancet Gastroenterol Hepatol. 2025-7

[7]
Universal HCV Screening in Hospitalised Patients in France: It Could Be a Good Option! The DEVICHO Study.

J Viral Hepat. 2025-6

[8]
Autoimmune manifestations and direct-acting antiviral drugs in Egyptian patients with hepatitis C virus infection: A cohort study.

J Int Med Res. 2025-5

[9]
Hepatitis C in North Africa: A Comprehensive Review of Epidemiology, Genotypic Diversity, and Hepatocellular Carcinoma.

Adv Virol. 2025-3-24

[10]
Global burden and trends of viral hepatitis among women of childbearing age from 1990 to 2021.

Front Microbiol. 2025-2-21

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索